Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Morgan Sanford
executiveThanks, Operator. Good morning, everybody, and thank you for being with us to go over Agios Pharmaceuticals' third quarter 2026 financial results and business highlights. The slides for today's call can be found in the Investors section of our website, agios.com. Next slide, please. I want to note that we will be making certain forward-looking statements today. Due to various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC, actual events and results could differ materially from those expressed or implied by any forward-looking statements. On the next slide, we have the agenda for today's call; joining me today from Agios are Brian Goff, Chief Executive Officer; Cecilia Jones, Chief Financial Officer; Tsveta Milanova, Chief Commercial Officer; and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development. After prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian.
Brian Goff
executiveThanks, Morgan. Good morning, everyone, and I appreciate you joining us. Next slide, please. For Agios, the third quarter brought record product revenue and clearly shows how well we are executing commercially; total net revenue came in at $55.4 million, which is more than 4x what we posted in the third quarter of last year. U.S. net revenue reached $48.7 million, fueled by the ongoing strong U.S. launch of AQVESME in thalassemia. For context, our total revenue from this one quarter exceeded what we generated across all of 2025; this result shows what we are building: a focused rare hematology company with a scalable commercial foundation. Thalassemia is the first launch to build on that foundation. Sickle cell disease is our biggest opportunity, and it's up next — I'll give you a quick update on where the mitapivat sNDA stands. We ended the quarter with $907 million in cash, cash equivalents, and marketable securities, which leaves us well capitalized to fund commercial launches and advance our focused pipeline. Let's go to the next slide. As I mentioned, everything is in place for us to execute the commercial launch of mitapivat in sickle cell disease. I want to take a moment to address the recent update on our sNDA directly. On October 9, as we disclosed last week, the FDA asked for additional information so it can determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is required for mitapivat in sickle cell disease. Our reply went back in 10 days, and it included roughly 9 months of extra safety data from the RISE UP open-label extension period. The FDA treated our response as a major amendment, which under the process adds 3 months to the review timeline, pushing it to February 1, 2027. Let me be clear on why we still have confidence in a possible approval in sickle cell disease: even with this added follow-up, no cases of liver injury in sickle cell disease have appeared that match the pattern or severity of those seen in thalassemia. For mitapivat in sickle cell disease, the benefit-risk profile has not changed. The FDA gave this application Priority Review in recognition of the serious unmet need, and that urgency remains the same. Talks with the agency about labeling are still underway, and that includes possible REMS components, and we are ready to launch. Our teams across commercial, medical, market access, and patient support are all in place, and we remain deeply engaged with the sickle cell community. Getting mitapivat to patients as fast as we can is what we are focused on. Let's go to the next slide. As we look forward, we are narrowing our focus to fuel the coming stage of growth. Our strategy is straightforward. First, we will maximize the mitapivat franchise, which holds approvals now in PK deficiency and thalassemia, while sickle cell disease acts as an additional growth driver starting in early 2027. Next, we’re concentrating on a lean rare hematology pipeline—this covers AG-236 for polycythemia vera, with plans to start a Phase 2/3 program before the end of the year, and sevidoplenib for immune thrombocytopenia, where a Phase 3 trial is scheduled for the first half of 2028. The important point is that clinical validation already exists for the mechanisms of action behind both programs, which lowers the risk. To support that tighter focus, we’ve resized our operating model accordingly. During 2026, R&D headcount will be more than 35% lower than in 2025—a reduction exceeding 100 roles—and we expect the associated cost savings to show up in 2027. We've narrowed our clinical investment to programs that stand apart in rare blood disorders, and we're exploring options to extract value from assets outside our core focus—including the vorasidenib royalty and AG-181. As a result, we'll continue keeping a tight grip on operating costs while directing investment toward our commercial rollouts and rare hematology pipeline prospects, aiming for non-GAAP profitability in 2028. That said, let's advance to the following slide, and I'll pass things over to Cecilia for the financial review. Cecilia?
Cecilia Jones
executiveThanks, Brian. Could we go to the next slide, please? Now for our third quarter financial results: total mitapivat net revenue came in at $55.4 million, which includes $48.7 million in the U.S. and $6.6 million outside the U.S., versus $12.9 million in total net revenue for the third quarter of 2025. Cost of sales during the quarter was $2.5 million, compared with $1.7 million in the prior-year period. Research and development expense totaled $73.5 million, versus $86.8 million in the third quarter of 2025, mainly reflecting lower spend tied to mitapivat and tebapivat process development and certain clinical trials. SG&A expense reached $56.5 million, up from $41.3 million a year earlier, driven by commercial efforts behind the AQVESME U.S. launch in thalassemia and groundwork for a possible U.S. sickle cell disease launch. Our net loss in the third quarter of 2026 totaled $65 million versus a net loss of $103.4 million in the third quarter of 2025; we ended the quarter holding $907 million in cash, cash equivalents, and marketable securities, which we believe provides the financial strength to support the AQVESME launch, a potential sickle cell disease launch, and advancement of our focused pipeline toward non-GAAP profitability in 2028. Moving on to how we see 2026: we expect operating expenses for the full year to remain roughly level with 2025. That figure leaves out two items — the $25 million upfront payment tied to the sevidoplenib in-licensing, which was recorded in the second quarter, and a one-time charge of about $11 million linked to the headcount reduction, which will be booked in the fourth quarter. Let's go to the following slide, and I'll hand things to Tsveta for the commercial highlights.
Tsveta Milanova
executiveThanks, Cecilia. Could we go to the next slide? Q3 was a record quarter for mitapivat, and the way the teams executed makes me proud, with total mitapivat revenues rising to more than 4x what they were in the third quarter a year ago. Within the U.S., net revenue rose 20% quarter over quarter, powered by excess demand throughout the broad thalassemia population, and I'll get into that in more detail shortly. Beyond the U.S., net revenue climbed 74% compared with the prior quarter, powered by early access programs in Europe that followed the European Commission approval for thalassemia in the second quarter; that's an early signal of the worldwide opportunity for mitapivat, which we're going after through a capital-efficient model alongside our partners, Avanzanite in Europe and NewBridge Pharmaceuticals in the GCC. Next slide, please. Now let's look at U.S. demand for AQVESME in thalassemia. As a reminder, when the patient and physician opt into our support program, an Agios Start Form gets submitted together with an AQVESME prescription. During the third quarter, we added 177 prescriptions from 135 physicians with completed start forms, which brings the total to 619 since launch — roughly 15% of our target launch population of about 4,000 patients, and we're only three quarters into launch. This is the final quarter in which we'll report this metric. So that you have a complete picture, another 48 prescriptions had start forms in process when the quarter ended. We said previously that first quarter start forms got a boost from pent-up demand that built up during the extended thalassemia FDA review period. What we're seeing now is the steady broadening we planned for into community practices and non-transfusion-dependent patients, where treatment decisions take more time. On persistency, about 75% of patients are still on therapy at roughly 6 months. That's exactly the foundation we want: a durable base of patients that builds over time. Looking ahead, two things have our focus. On persistency, making sure prescribers are aware of the long-term clinical data we've generated so that patients stay on treatment long enough to benefit. On demand, we're expanding our reach in the community setting, deepening adoption among transfusion-dependent patients, and driving uptake in non-transfusion-dependent patients. We're also activating patients themselves through the first direct-to-consumer campaign. Next slide, please. In August we launched Level Up with AQVESME, our first direct-to-consumer campaign, a targeted omnichannel effort; this month we're expanding it with multilingual assets to reach the diverse thalassemia community. Early results are encouraging, and following the launch we saw a 65% increase in engagement on our patient website. Please move to the next slide. Feedback from treating physicians keeps reinforcing the value of AQVESME in thalassemia. Recent market research shows broad enthusiasm across both transfusion-dependent and non-transfusion-dependent segments; the momentum three quarters into launch encourages us. As the first medicine approved for the broad thalassemia population, AQVESME is well positioned for continued growth, and I'm confident in our team's ability to deliver. Next slide, please. Turning to sickle cell disease. Like Brian mentioned, we're ready for launch, and we'll take the extra time to get even further ahead before our February 1 PDUFA goal date. In the U.S., there are roughly 75,000 diagnosed patients who are 16 and older. At first, our launch will concentrate on about 25,000 patients who are either actively treated or need therapy. Those with a hemolytic profile characterized by low or declining hemoglobin will get priority from us; this targeted strategy is meant to speed adoption. This launch rests on the commercial groundwork we built for thalassemia in an initial launch population that is more than 6x bigger — roughly 25,000 patients — versus about 4,000 for thalassemia. Our dedicated sales, medical, and patient support teams are hired and trained. Manufacturing and supply chain are set for day-one availability, and we've mapped the priority physicians. If the FDA approves, we're well positioned to bring mitapivat, the first oral PK activator, to people living with sickle cell disease. Please go to the next slide, and with that, I'll turn the call over to Sarah for R&D highlights. Thank you, Sarah.
Sarah Gheuens
executiveMoving to the next slide, please. Our pipeline is centered on strengthening our lead position in rare hematology. Mitapivat serves as the portfolio's foundation, with wide global approvals in PK deficiency and thalassemia. For sickle cell disease, we're in labeling talks with the FDA, covering components of a possible REMS, and we've submitted for approval in Saudi Arabia; we're also continuing to move our pediatric thalassemia program forward. ENERGIZE-Kids and ENERGIZE-Kids T could grow our addressable U.S. thalassemia population by roughly 2,000 pediatric patients. Past mitapivat, we're moving sevidoplenib in immune thrombocytopenia toward a Phase 3 trial set for the first half of 2028, and AG-236 in polycythemia vera toward a Phase 2/3 program by year-end. Finally, we expect proof-of-mechanism results for AG-181 in phenylketonuria prior to the close of this year. Let's move to the next slide. We look forward to presenting fresh clinical data at the 2026 American Society of Hematology Annual Meeting happening next month, covering our rare hematology portfolio, as the abstracts that came out yesterday indicated. Come December, we'll share new clinical findings from the RISE UP Phase 3 trial that we believe substantially distinguish mitapivat's profile in sickle cell disease, regarding hemoglobin and other measures as well, possibly stemming from mitapivat's unique mechanism of action that targets PKR, found in red blood cells, along with PKM2, found in organ tissues. To begin with durability: throughout the open-label extension period, hemoglobin gains remain stable, and more patients continue to demonstrate response as treatment goes on. During the open-label extension, 62.7% of patients saw their hemoglobin improve, and that figure includes 39.7% of patients who had not responded at the start; hemoglobin responses lasted as long as 115 weeks in the open-label period. Next, post hoc analyses of RISE UP are beginning to yield kidney and cardiac findings. With sickle cell disease, an abnormally elevated eGFR — that is, hyperfiltration — serves as an early indicator of kidney damage. In patients who had hyperfiltration, mitapivat brought eGFR down closer to normal, with a mean change of 14.7 compared with 4.9 on placebo at Week 52. Notably, this kidney effect did not depend on hemoglobin response, which points to a possible PKM2-mediated effect that goes beyond correcting anemia. For hemoglobin responders, the heart showed favorable remodeling, with left ventricular mass index dropping by an average of 5.9 grams per meter squared; non-responders saw a rise of 5.8, and those on placebo a rise of 4.6. Left atrial volume likewise went down, which supports the possibility of a disease-modifying benefit. Taken together, these findings indicate that mitapivat's unique effect on PKM2 could tackle organ damage—a major contributor to early death in sickle cell disease. Let's go to the next slide. In addition, at ASH 2026 we will share the first clinical data on AG-236, our siRNA aimed at TMPRSS6 inhibitor for polycythemia vera, drawn from our Phase 1 trial in healthy volunteers. AG-236 works by boosting hepcidin, thereby reducing the iron that's available for making red blood cells — a mechanism that can keep hematocrit under control in polycythemia vera. At Day 29, a single dose drove hepcidin up by as much as 24 micrograms per liter, whereas placebo showed a decline. AG-236 also brought down transferrin saturation and hematocrit, and those impacts on iron, transferrin saturation, hemoglobin, and hematocrit remained stable all the way through Month 6. AG-236 was well tolerated — all adverse events were Grade 1 or 2, with no serious adverse events and no discontinuations. This durability from a single dose supports the potential for dosing every six months, and feedback from key opinion leaders around the world describes it as a possible paradigm shift in treating polycythemia vera. We're eager to present the complete 6-month data at ASH next month and to update you on how this program is progressing, with Phase 2/3 trial initiation expected by the end of this year. Next slide, please. Before we get to Phase 1b proof-of-mechanism data, we are sharing preclinical data for AG-181 for the first time—our novel PAH stabilizer being developed to treat phenylketonuria, or PKU; in our preclinical model of classical severe PKU, AG-181 yielded significant dose-responsive decreases in blood phenylalanine, and at 300 milligrams per kilogram we reached a clinical target of below 360 micromolar with no diet modification. At the Society for the Study of Inborn Errors of Metabolism 2026 Annual Symposium, we presented our Phase 1 healthy volunteer study. In that study, human exposures at our Phase 1b doses landed comfortably inside the efficacious exposure range observed in mice. AG-181 was well tolerated, with no serious adverse events, no Grade 3 or higher adverse events, and no discontinuations. Its pharmacokinetic profile supports twice-daily dosing in our ongoing Phase 1b study in PKU patients. We believe AG-181 offers a meaningfully differentiated mechanism for treating PKU, supported by compelling preclinical data and Phase 1 data in healthy volunteers. We’re eager to extend that groundwork through Phase 1b proof-of-mechanism results in PKU patients prior to year-end, and we think this will set the program up for additional development and for a possible role as a transformative medicine for this community. With that, please advance to the following slide, and I’ll return the call to Brian for closing remarks.
Brian Goff
executiveThanks, Sarah. Could we move to the next slide? Agios is a rare hematology company with a sharp focus, and we're entering our next stage of growth. For thalassemia, AQVESME holds the distinction of being the first medicine approved for the broad patient population, and its U.S. launch produced record net product revenue in the quarter; momentum is strong, and AQVESME keeps fueling growth as we head toward year-end. On sickle cell disease, we're ready to launch ahead of our PDUFA goal date of February 1, and a growing body of data backs mitapivat's strong anti-hemolytic profile along with differentiated organ health benefits. Beyond mitapivat, our pipeline is focused: AG-236 for polycythemia vera and sevidoplenib for immune thrombocytopenia, each with clinically validated, de-risked mechanisms of action, plus strategic optionality from AG-181 in PKU. We're executing with discipline, right-sizing the operating model, and directing capital toward the opportunities where we believe Agios can create the most value for patients and shareholders. Before opening the call for questions, I want to thank the whole Agios team. Their focus and dedication produced a record quarter while we prepared for our next potential launch; with that, thanks to all of you for joining us today. Operator, we're ready to start the question-and-answer session.
Alec Stranahan
analystThere are a couple of things I'd like to ask about: first, the PDUFA delay, and second, the ASH presentations. Beyond the REMS, has the FDA brought up anything else, like the age range or any of the clinical endpoints? And should a REMS be needed, how would that affect your launch expectations along the curve compared with what you've observed in thalassemia? Then, on the ASH updates, the durable hemoglobin gains seen at up to 2 years, together with the kidney and heart signals, look incremental relative to earlier presentations. How do you see these benefits comparing against competing drugs, particularly regarding the PKM2 activation you highlighted?
Brian Goff
executiveThanks, Alec. We'll go through that in order, then. Let's start with your PDUFA question, and that one has two parts. Sarah can kick things off and comment on where things stand with the FDA, and then Tsveta can address the commercial side, and we'll handle the second question on its own.
Sarah Gheuens
executiveThanks, Alec. Regarding the PDUFA delay and the other potential questions that have come up, our engagement with the agency is going very well. We pointed out that we're in labeling negotiations. We have confidence in the benefit-risk profile of our drug, and we look forward to working with the agency as quickly and expeditiously as we can to bring this much-needed drug to patients.
Tsveta Milanova
executiveYes, absolutely. From our perspective, the PDUFA delay really amounts to a shift in timing rather than any change to the commercial opportunity. As everyone knows, sickle cell disease impacts roughly 100,000 patients across the U.S., and it will be the biggest indication we are going after at present. Those 25,000 patients, whom we pinpointed as our initial launch target, are ready for us to launch in any scenario, and we already have a very solid commercial infrastructure in place to make that happen.
Brian Goff
executiveAbsolutely, and I want to add emphasis to what Tsveta just mentioned as well. Tsveta and her team are always getting ready for a range of scenarios. And at this point, I believe this particular quarter really shows how much groundwork went into thalassemia with AQVESME; and here we are making steady headway, and we'll take the same approach with sickle cell.
Sarah Gheuens
executiveNow, on your other question about the incremental data — I have to say, I’m genuinely proud of what we have here. This is fresh information, and what it shows is that mitapivat may offer a real benefit when it comes to improving organ health, in both the kidney and the heart, and those are, of course, two key organs driving mortality among people with sickle cell disease. So for us, seeing these results was truly exciting; it also underscores what PKM2 can do, which is, of course, a mechanism unlike any other that we have. We are a pan-PK activator, so there really isn’t a competitor out there with this mechanism. So we’ll keep putting these data front and center, we’ll differentiate through that dual mechanism of action, and we very much look forward to ASH.
Alec Stranahan
analystAll right, thank you once more.
Samantha Semenkow
analystThere are a couple of things I'd like to ask about too, and both concern sickle cell disease. First, could we go into a bit more depth regarding the kinds of possible scenarios for how a REMS might be structured for sickle cell disease? From what we understand, those requirements come in differing levels. Then, turning to competition, might you expand in greater detail on where you expect mitapivat to sit commercially? And when we head toward ASH and start making cross-trial comparisons against competitors, is there anything about trial design we ought to bear in mind while doing that?
Brian Goff
executiveThank you, Sam. Sarah, would you like to take those two questions first?
Sarah Gheuens
executiveAnd then perhaps pass it over to Tsveta too for the positioning side. On your first question, Sam, about possible REMS scenarios, you're correct that REMS vary enormously. Certain ones concentrate only on educational pieces, a medication guide, say, whereas you also have an entire spectrum extending to a REMS featuring elements to assure safe use, an ETASU REMS, which resembles the AQVESME-style REMS more closely. As we've pointed out, we're currently negotiating with the FDA over a label that contains components of a possible REMS. That's genuinely everything we can say right now; regarding ASH and cross-trial comparisons, whenever we examine any trial in sickle cell disease, naturally we'd be reviewing baseline demographics of a patient population, the locations where patients were enrolled, baseline VOC rates, so as to grasp treatment effects that have been discussed. So those are items I would certainly suggest when you undertake cross-trial comparisons. And then, naturally, another dimension apart from efficacy is safety data, since in the end what matters is a drug's benefit-risk profile. And then regarding competitive positioning, I'll actually pass that to Tsveta.
Tsveta Milanova
executiveCertainly. As I mentioned, we are prepared for launch, and we are enthusiastic about the possibility of approval for sickle cell disease. As I noted, we have identified roughly 25,000 patients, and those represent our initial launch targets; we are drawing on very strong data in sickle cell disease, and these are individuals who are in fact actively interacting with the healthcare system, are seen by hematologists, and have the potential to demonstrate a need for therapy, which is excellent. The three elements around which we will seek to position the drug begin, of course, with the clinical data. The clinical data is very widely recognized and accepted by treating hematologists; we have received very positive feedback, both regarding the consistency and the strength of the anti-hemolytic profile. And as Sarah mentioned, we keep generating data, both in the open-label extension and through additional data to substantiate the clinical differentiation. A second very important element is our market experience and the totality of our safety exposure built up over the years. It is important, of course, for clinicians to feel confident in the profile, but it is critically important in a disease like sickle cell disease, where patients themselves are highly safety conscious. And we view that as a strength; and last but not least is the trust that we have established with this community. We have been on the market with Pyrukynd for several years now, and we have a well-established not only medical and clinical development, but commercial infrastructure, which is in place and engaging with these customers, and we will leverage all of that.
Samantha Semenkow
analystThank you so much.
Eric Schmidt
analystPerhaps regarding the financial aspect and Cecilia's R&D cost reductions, could you provide an estimate of how much savings we're talking about, or where you expect that R&D spending to land on a 2027 basis — or even what revenue would be required in 2028 for us to reach that non-GAAP break-even profitability?
Cecilia Jones
executiveThanks, Eric. Where OPEX is concerned, what we've pointed to is a reduction in our R&D headcount of roughly 100 heads, or 35%, over the course of 2026; and we'll record a one-time charge of $11 million in Q4 of 2026. The benefit of the savings from those reductions will show up in 2027, given that most of them come toward the end of 2026. We aren't giving guidance at this point. It's a bit early for 2027. As for the 2028 non-GAAP profitability target, we are factoring in the possible launch of sickle cell in 2027 along with a disciplined approach to how we manage our OPEX.
Eric Schmidt
analystAll right, perhaps I could pose a somewhat technical question to Sarah regarding the REMS components in sickle cell that are under discussion. Could you have a distinct REMS program for sickle cell compared with the one for thalassemia and still get approval under the same brand name, AQVESME, or if it were at a slightly different range, would that call for a third brand name?
Sarah Gheuens
executiveThank you, Eric, for asking. Any of those options are always on the table. There's a full spectrum of brand names and REMS types. We're unable to comment right now on label negotiations that are ongoing. We'll genuinely be eager to get these finished. I believe Sam mentioned the range of possible REMS, and so every one of those remains an option.
Eric Schmidt
analystAll right, thanks.
Gregory Renza
analystThis is Nishant calling in for Greg. To begin with AQVESME, of those 177 completed start forms along with the 48 new ones, what share came from NTD patients as opposed to TD patients? Also, what's behind the sequential moderation? Then, regarding AG-236 and the therapeutic window, why are you confident that the 6-month effects seen in healthy volunteers will carry over into sustained phlebotomy control in PV without causing excessive iron restriction or anemia? Thanks so much.
Brian Goff
executiveTsveta, would you like to begin with AQVESME and the continued progress we're making?
Tsveta Milanova
executiveCertainly. The launch's first three quarters have us feeling quite positive. We're in the process of establishing the thalassemia market, and AQVESME is genuinely the first medicine to gain approval for this wide thalassemia patient population. We aren't disclosing the TDT versus NTDT breakdown, but it's very gratifying to watch demand keep widening across both segments: transfusion-dependent patients, along with growth among non-transfusion-dependent patients. That's excellent. Looking at performance overall, 619 prescriptions originate from start forms — those are completed start forms — representing roughly 15% of the total patient population, and a further 48 prescriptions reflect upstream demand, which remains in process and forms part of the demand funnel. So from our standpoint, that is extremely, extremely encouraging. Yet, crucially as we go forward, I want to stress the persistency point. We shared that the initial persistency we're currently observing at 6 months stands at 75%. That figure is likely among the most critical elements, since thalassemia is a chronic disease and future revenues will really consist, naturally, of new patients beginning therapy, but increasingly of patients staying on therapy.
Brian Goff
executiveAnd Nishant, internally we spend a lot of time discussing how healthy the launch is and how we build on our experience in rare disease; what Tsveta just outlined is exactly the kind of thing we're looking for, which is that three quarters in, we continue to make really solid progress into a very substantial opportunity, with breadth across prescribers and breadth across patient types. As Tsveta mentioned a moment ago, we provided some color on that today. Persistency and all of that comes together into very healthy dimensions that please us quite a bit. And, naturally, we're going to look to amortize all these learnings into a potential sickle cell disease launch as well. And Sarah?
Sarah Gheuens
executiveRight. Then, regarding your question about AG-236 and iron restrictive anemia as we go from healthy volunteers into patients — that's obviously the reason we're conducting the Phase 2 study, to do proper dose finding in patients. We're very excited about the data that will be presented at ASH, which lets us move forward into patients. Based on those data, we believe we truly have an opportunity to bring this dosing frequency to an every-six-month dose; that will be the aim of the Phase 2, to test this across a range of doses and a range of frequencies. And then we're very excited, once we have that data, to move seamlessly into Phase 3.
Gregory Renza
analystMany thanks.
Douglas Tsao
analystSo, regarding the AQVESME launch, I'm just wondering: when it comes to that 75% persistence, which is truly impressive, is there any difference at this point between the non-transfusion-dependent and transfusion-dependent patients?
Tsveta Milanova
executiveFor sure. Those early signs of persistency have us quite encouraged, with 75% of patients continuing past the 6-month mark; strong persistency is showing up across patient segments. And that was in fact also the case for the PK deficiency indication, so seeing it in thalassemia as well is wonderful.
Douglas Tsao
analystAnd just to follow up on that, I'm wondering whether, given the data that came out at EHA last year, you've gotten the sense that clinicians are now more open to trying extended treatment with patients than they might have been before that data set?
Tsveta Milanova
executiveYes, definitely. In the real world, I think the benefit of AQVESME is defined much more broadly than what we see in the clinical trial. For regulatory purposes, the trial criteria are extremely specific and clearly defined, but of course people are also looking at how patients feel as well as their hemoglobin increases; and here I also want to point out that we have excellent payer coverage. The team has done a phenomenal job, and within 6 months of launch, we have payer coverage policies for 75% of covered lives, and they are very, very favorable for AQVESME, so we have no prior restrictions.
Douglas Tsao
analystAll right, that's great. Thanks a lot, and congratulations on the progress.
Analyst
analystHello, I'm Amanda, calling in for Andrew Berens. If a REMS does come up during the sickle cell review, could you lay out what the possible options might be on pricing and brand strategy? Thank you.
Brian Goff
executiveThank you, Amanda. Tsveta, would you like to handle that one? And naturally, we never go into specifics on pricing, though I believe we can give some shape to how we're thinking about it.
Tsveta Milanova
executiveCertainly. So, from a payer's viewpoint, sickle cell disease remains a rare condition—one with a very high unmet need and no treatment options. As we've said, we're preparing for every launch scenario, but regardless of which scenario plays out, we believe we can sustain, at one level, rare disease pricing that's very similar to what we have with Pyrukynd and AQVESME, given how strong the value proposition of mitapivat is in the sickle cell disease indication. Naturally, sickle cell disease involves a somewhat larger Medicaid patient population, and that will have an impact on the gross-to-net, but from a pricing perspective we are very well positioned.
Joseph Thome
analystFirst question on the pipeline: for the upcoming proof-of-concept data in PKU, what should we be expecting? What would count as encouraging there, and perhaps in light of your updated R&D focus and the headcount reduction, does this stay within your focus, or might you look to out-license it as an asset? Thank you.
Sarah Gheuens
executiveRegarding proof-of-mechanism data in PKU patients, clearly safety is what we're after since it's a Phase 1b, but beyond that we're also examining Phe reductions, which is the classic way one would assess it from a PKU perspective. We think this program then offers us the potential for further development, and so that's something we're excited about.
Brian Goff
executiveYes, and I'll add too — as I said earlier in my remarks — that PKU represents a significant unmet need, even if it isn't in hematology; and the initial step, naturally, is to obtain the data, which we're keen to see; and I mentioned that we preserve optionality. So we definitely hold the choice of retaining it within our portfolio. We're aware as well that considerable interest exists in PKU more broadly, as a market that keeps evolving and expanding, and so we believe we're in a strong position to have that option available.
Joseph Thome
analystGreat. Thank you.
Brian Goff
executiveYou bet.
Tessa Romero
analystI'd like to direct a question to Tsveta. During the third quarter, 177 AQVESME prescriptions were written with completed Agios Start Forms. As we move forward in your launch, what's the right way to think about the run rate for that script add each quarter? And my second question concerns the 75% of patients who remain on therapy after 6 months. In the marketplace, what are you seeing regarding why patients discontinue, if they do? Thank you.
Tsveta Milanova
executiveSure. Absolutely. On your first question, what I'll point to is this: look at the first three quarters in totality — we reported 619 prescriptions with completed start forms, plus an additional 48 in progress, which puts us at roughly about 15% of the total addressable patient population for thalassemia for our launch target, and that's a very good start for a chronic disease that is not imminently life-threatening. When you look at how things evolved quarter over quarter, Q1, as we've already highlighted, and to a lesser extent Q2, really benefited from that pent-up demand built during the extended EAP period. We're now seeing the broadening — which we always expected and planned for — into the community as well as the non-transfusion-dependent patients, where treatment decisions take more time. Looking ahead, the 177 is probably the more appropriate run rate as we continue to penetrate these markets. I'll highlight it again: given the chronic nature of the disease, one element we're very excited about is also the hybrid system we're seeing from the initial stages of the launch, because moving forward, of course, revenues will be driven by both the new patient starts and patients on therapy as well.
Salveen Richter
analystBefore the PDUFA date in sickle cell disease, could you address how physicians overlap with thalassemia and how comfortable they'd be with a possible REMS inclusion here?
Tsveta Milanova
executiveAbsolutely. Obviously, we stay in regular touch with the physician community. The team is engaged, and we're doing extensive account profiling, and Brian and I also held virtual meetings over the last few months to connect with sickle cell disease caregivers at various forums. And I can tell you there's a very high level of engagement and excitement, both about the profile and about the potential approval for the product. When we think about hematologists, the three hemolytic anemias, the overlap really will exist mainly in the academic setting. We haven't given specifics on that overlap, and this is mainly driven by the fact that at the same center you might have hematologists focusing on hemolytic anemia, but some of them specialize in thalassemia and might specialize in sickle cell disease. Otherwise, in the community, every hematologist treats both conditions, both thalassemia and sickle cell disease.
Luca Issi
analystTsveta, regarding those 619 cumulative prescriptions for AQVESME plus the additional 48 — do they all come from thalassemia, or are some of them already from sickle cell disease? We talked with a physician recently who said she had already started 10 to 15 of her sickle cell patients on this drug, and she reported fairly little pushback from Medicaid, whereas she says there's considerably more resistance on Medicare and commercial. So I'm wondering whether that doctor is just an outlier, or whether a meaningful share of the 619 is in fact already coming from sickle cell. Any insight on that would be much appreciated. Then, Cecilia, going back to Eric's question: as the P&L keeps maturing and you begin to see non-GAAP profitability approaching for 2028, do you plan to actually guide on the top line and perhaps the expense line in 2027, or would that be too early? Thanks so much.
Brian Goff
executiveTsveta, let's begin with the question about the 619 and the 48.
Tsveta Milanova
executiveYes, and I want to make sure there's no ambiguity here: the 619 and the 48 both represent thalassemia prescriptions that are on-label.
Brian Goff
executiveYeah. And then, Cecilia, I’ve got a question about the P&L as well as future guidance and so forth.
Cecilia Jones
executiveLuca, giving guidance for 2027 is a bit premature, though we plan to offer it at the right moment.
Luca Issi
analystGot it. Thanks so much.
Cecilia Jones
executiveThank you.
Brian Goff
executiveThank you. Appreciate everyone being here today. As we mentioned, Agios achieved record product revenue during the third quarter. In thalassemia, AQVESME is developing a durable and expanding patient base, while sickle cell disease represents the biggest potential opportunity we have. Ahead of our February 1, 2027 PDUFA goal date, we are ready for launch. With more than $900 million in cash and a disciplined operating model, we are well positioned to execute as we aim for non-GAAP profitability in 2028. We look forward to sharing updates on our progress, including at our upcoming virtual ASH investor event on December 14, where we will feature new clinical data for mitapivat in sickle cell disease, further strengthening our profile, along with 6-month healthy volunteer data for AG-236, which, as Sarah noted, supports every-six-month dosing — meaning we have the potential to deliver a best-in-class medicine for treating polycythemia vera. Thank you very much, and we look forward to speaking soon.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone joining us. You're welcome to disconnect your lines at this point. Please note that this live transcript is generated automatically, with no human involvement or review.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.